OVERVIEW
Buprenorphine is a partial \( \mu \)-opioid agonist used with or without naloxone, an opioid antagonist, via transmucosal delivery to treat patients with opioid dependence (or a moderate-to-severe opioid use disorder). Though effective, a clinical strategy of using transmucosal buprenorphine is prone to nonadherence, diversion, abuse, and accidental misuse. To lower these risks and to improve adherence, Braeburn Pharmaceuticals devised buprenorphine (Probuphine), an implant to provide sustained delivery of buprenorphine for up to 6 months when 4 rods are inserted subdermally. It is intended as a maintenance treatment for a selected subgroup of opioid-dependent patients who are clinically stable on a low dose of transmucosal buprenorphine (\( \leq 8 \text{ mg/d} \)). These implants are inappropriate for new treatment recipients or those who have not sustained and prolonged clinical stability, while being maintained or a generic equivalent.

MEDICAL CRITERIA
Not applicable.

PRIOR AUTHORIZATION
Prior authorization review is not required.

POLICY STATEMENT
Buprenorphine subdermal implants is considered medically necessary for individuals who have been diagnosed with opioid dependence; have been treated with a stable transmucosal buprenorphine dose without any need for supplemental dosing or adjustments; are currently on a maintenance dose of a sublingual Subutex or Suboxone tablet or its transmucosal buprenorphine product equivalent to achieve sustained prolonged clinical stability and implants will be used as part of a comprehensive substance use disorder treatment program that includes counseling and psychosocial support.

Use of buprenorphine implants greater than 2 times per lifetime are not medically necessary as the the FDA labeling prohibits use after two 6-month doses.

Under the Drug Addiction Treatment Act (DATA) codified at 21 United States Code (U.S.C.) 823(g), use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe or dispense this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable physician administered drug benefits/coverage.

BACKGROUND
Buprenorphine is among the main options in a medication-assisted treatment strategy for opioid dependence. Transmucosal buprenorphine products have a potential for diversion to an illicit drug market and have resulted in accidental poisonings of small children. \(^1\) To minimize the misuse, Braeburn Pharmaceuticals developed Probuphine, an implantable buprenorphine that would be difficult to divert or abuse, and would less likely be accidentally ingested by children. Further, it would maximize adherence passively for 6 or 12 months.
The initial new drug application (NDA) submitted by Braeburn in October 31, 2012, sought approval of buprenorphine implants for initial treatment of patients with opioid dependence after just a few days of titration on a transmucosal formulation. The Food and Drug Administration issued a complete response letter for this NDA, stating that, although the two 6-month trials met the prespecified end points, the dose provided by the implant was too low to be effective for patients new to buprenorphine treatment. However, data from a subset of patients showed that 4 buprenorphine implants yielded buprenorphine concentrations similar to those observed with sublingual buprenorphine 4 to 8 mg based on average exposure (eg, mean area under the receiver operating characteristic curve values) or concentration. Thus, a subset of patients stabilized on sublingual buprenorphine 8 mg or less could benefit from buprenorphine implants, which is the current target population for which these implants are approved.

For individuals who are addicted to opioids but stable on low-to-moderate doses of transmucosal buprenorphine who receive buprenorphine implants, the evidence includes 1 randomized controlled trial. Relevant outcomes are change in disease status, morbid events, health status measures, medication use, and treatment-related morbidity. In the pivotal trial, the proportion of patients who reported for no more than 2 out of 6 months any evidence of illicit opioid use was similar between the buprenorphine implant arm (63%) and the sublingual buprenorphine arm (64%). The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome in a selected subgroup of patients.

REGULATORY STATUS
On May 26, 2016, buprenorphine (Probuphine; Braeburn Pharmaceuticals) was approved by the U.S. Food and Drug Administration (FDA) through the new drug application process for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of an agent containing transmucosal buprenorphine (ie, doses of ≤8 mg/d of Subutex or Suboxone sublingual tablet or generic equivalent).

PROBUPHINE is available only through a restricted program under a REMS, called the PROBUPHINE REMS Program, because of the risk of complications of migration, protrusion and expulsion, and nerve damage associated with the insertion and removal of PROBUPHINE [see Warnings and Precautions]. Healthcare Providers who Prescribe PROBUPHINE must be certified with the program by enrolling and completing live training. Patients must be monitored to ensure that PROBUPHINE is removed by a healthcare provider certified to insert PROBUPHINE implants. PROBUPHINE will only be distributed to certified prescribers through a restricted distribution program.

CODING
The following code should be used for the insertion:
17999: Unlisted procedure, skin, mucous membrane and subcutaneous

The following code is covered:
J0570  Buprenorphine implant, 74.2 mg

RELATED POLICIES
None

PUBLISHED
Provider Update January 2017

REFERENCES:
1. Notes from the Field: Emergency Department Visits and Hospitalizations for Buprenorphine Ingestion by Children – United States, 2010-2011” Centers for Disease Control and Prevention, January 23, 2013.
2. FDA Briefing Information for the January 12, 2016 Meeting of the Psychopharmacologic Drugs Advisory Committee U.S. Food and Drug Administration. .
3. FDA Slides for the January 12, 2016 Meeting of the Psychopharmacologic Drugs Advisory Committee. U.S. Food and Drug Administration. 
5. Braeburn Slides for the January 12, 2016 Meeting of the Psychopharmacologic Drugs Advisory Committee. U.S. Food and Drug Administration. 

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.